IFF Secures $1B Term Loan to Refinance €800M Notes

The $1.0 billion term loan directly replaces €800 million of euro-denominated senior notes, altering IFF’s near-term liability mix by shifting that exposure into a term loan facility. For investors tracking capital structure, the move changes the composition of interest-bearing debt and currency denomination of the refinanced principal. IFF reported FY 2025 net sales of $10.890 billion and total adjusted operating EBITDA of $2,086 million. Those operating metrics provide scale and earnings capacity that underlie the company’s ability to service debt. The company also completed notable portfolio activity in 2025, including the divestiture of Pharma Solutions (May 1, 2025), which produced a partial-year Pharma contribution of $369 million in net sales and a related loss on disposal recorded in 2025. Investors should view the term loan in the context of IFF’s broader financial position and recent portfolio changes.

IFF faced material principal repayments in 2025, totaling $2.913 billion. While those maturities were concentrated in the prior year, the new $1.0 billion facility addresses a specific outstanding euro note position and reduces that particular instrument from IFF’s public note schedule. The transaction therefore affects the company’s debt maturity profile and currency mix, though details such as new maturity date, covenant package, or interest terms were not disclosed in the provided material. Because IFF operates and reports significant international operations (notably Europe, Greater Asia, North America and Latin America), changes in debt currency composition can interact with FX translation exposure—an identified macro risk for the company.

IFF’s business spans Food Ingredients, Taste, Scent, and Health & Biosciences (H&B), with FY 2025 net sales split as follows: Food Ingredients $3,278M (30.1%), Taste $2,481M (22.8%), Scent $2,479M (22.8%), H&B $2,283M (21.0%), and a partial-year Pharma contribution of $369M (3.4%). Adjusted operating EBITDA by segment totaled $2,086M, led by H&B and Scent. The financing move should be read alongside ongoing operational priorities disclosed for 2025: portfolio optimization through divestitures, segment reorganization (Nourish split into Taste and Food Ingredients in Q1 2025), and cost/productivity initiatives. IFF invests materially in R&D across segments (e.g., Scent $241M, H&B $219M, Taste $172M in 2025), which supports product differentiation but does not, per filings, constitute a structural economic moat. Investors should assess how incremental debt fits with capital allocation to R&D, restructuring, and sustainability efforts.

Key risks flagged in IFF’s disclosures remain relevant after the refinancing: ongoing legal and regulatory investigations tied to fragrance businesses (with associated legal fees and provisions), environmental and product regulatory compliance costs, raw material price volatility (botanicals, commodity crops) and FX translation exposure. The company’s filings also note prior accounting revisions in the 2025 10-K related to various tax and accounting items; these do not indicate an annual impact but are material disclosures investors track. Separately, the company faces competitive pressure from large global peers and regional players; filings characterize IFF as lacking a sustainable economic moat, with competitive advantage derived from operational execution, R&D platforms and supply chain management rather than enduring structural protections.